Medicus Pharma advances Teverelix Phase 2 study after FDA feedback, IRB approval
Yahoo Finance · Jul 16, 2026 · Medicus Pharma Ltd. Warrant (MDCXW)
Medicus Pharma (NASDAQ:MDCX) said it has received US FDA feedback and central Institutional Review Board approval for its optimized Phase 2 study of Teverelix in men following a first episode of acute urinary retention. The redesigned study, designated ANT-2111-02, is expected to enroll...
Not investment advice. Cached headline, not a full reprint.